174 related articles for article (PubMed ID: 21229880)
1. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
[TBL] [Abstract][Full Text] [Related]
3. [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme].
Li CM; Liu XG; Lin XC; Chen XW; Liang NC
Ai Zheng; 2008 Aug; 27(8):809-15. PubMed ID: 18710613
[TBL] [Abstract][Full Text] [Related]
4. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
5. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
[TBL] [Abstract][Full Text] [Related]
6. Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro.
Schneider CC; Kartarius S; Montenarh M; Orzeszko A; Kazimierczuk Z
Bioorg Med Chem; 2012 Jul; 20(14):4390-6. PubMed ID: 22698781
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2.
Najda-Bernatowicz A; Łebska M; Orzeszko A; Kopańska K; Krzywińska E; Muszyńska G; Bretner M
Bioorg Med Chem; 2009 Feb; 17(4):1573-8. PubMed ID: 19168362
[TBL] [Abstract][Full Text] [Related]
8. Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2.
Gianoncelli A; Cozza G; Orzeszko A; Meggio F; Kazimierczuk Z; Pinna LA
Bioorg Med Chem; 2009 Oct; 17(20):7281-9. PubMed ID: 19748274
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of novel polybrominated benzimidazole derivatives-potential CK2 inhibitors with anticancer and proapoptotic activity.
Łukowska-Chojnacka E; Wińska P; Wielechowska M; Poprzeczko M; Bretner M
Bioorg Med Chem; 2016 Feb; 24(4):735-41. PubMed ID: 26778657
[TBL] [Abstract][Full Text] [Related]
10. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
13. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
14. Resorufin: a lead for a new protein kinase CK2 inhibitor.
Sandholt IS; Olsen BB; Guerra B; Issinger OG
Anticancer Drugs; 2009 Apr; 20(4):238-48. PubMed ID: 19177021
[TBL] [Abstract][Full Text] [Related]
15. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
16. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
17. Proapoptotic effects of new pentabromobenzylisothiouronium salts in a human prostate adenocarcinoma cell line.
Koronkiewicz M; Kazimierczuk Z; Szarpak K; Chilmonczyk Z
Acta Pol Pharm; 2012; 69(6):1325-33. PubMed ID: 23285698
[TBL] [Abstract][Full Text] [Related]
18. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
[TBL] [Abstract][Full Text] [Related]
20. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
Schneider CC; Hessenauer A; Montenarh M; Götz C
Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]